Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.
Adrian Murray Brunt, Joanne S Haviland, Mark Sydenham...
https://pubmed.ncbi.nlm.nih.gov/32663119/Actively Recruiting
Led by University Health Network, Toronto · Updated on 2026-07-17
171
Participants Needed
19
Research Sites
N/A
Total Duration
This research aims to evaluate a shorter, 1-week course of partial breast re-irradiation rPBI after breast-conserving surgery for women with recurrent or new primary breast cancer in a previously irradiated breast. The study focuses on women who have had prior whole breast radiation and now face local recurrence, assessing whether this ultra-hypofractionated radiation approach results in acceptable levels of toxicity at one year. This approach is thought to reduce side effects and improve cosmetic outcomes compared to traditional longer treatments or mastectomy. Participants receive external beam rPBI delivering 26 Gy in 5 daily fractions over one week following a second lumpectomy. This phase 2, single-arm, multi-institutional trial enrolls women with localized recurrence or new cancer in the previously irradiated breast. The treatment aims to be more convenient with fewer sessions while maintaining safety and effectiveness, advancing knowledge on optimal care for this patient group. During the study, participants will undergo regular assessments of radiation-associated toxicity, recurrence risk, survival, and quality of life at multiple time points up to five years post-treatment. Evaluations include physical exams, imaging, and questionnaires on breast satisfaction and financial impact. The primary outcome is grade 3 or higher toxicity during the three-year accrual period. This long-term monitoring ensures safety and gathers data on treatment effects over time.
CONDITIONS
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
D
Danielle Rodin, MD
A
Anne Koch, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Health Network, Toronto
Lead Sponsor
Sunnybrook Health Sciences Centre
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | rPBI (26Gy/5 fractions in 1 week, ultra-hypofractionation) | Current-care: Partial breast reirradiation (standard fractionation) or mastectomy |
|---|---|---|
| What it is | Ultra-hypofractionated partial breast reirradiation using external beam radiotherapy, delivered as 26 Gy in 5 daily fractions over one week. | Partial breast reirradiation using standard fractionation (typically 3D conformal RT or brachytherapy, delivered over longer schedules) after breast-conserving surgery, or mastectomy as an alternative in select cases. |
| Role in trial | Single-arm investigational therapy evaluated for toxicity, local control, and patient satisfaction in women with recurrent/new primary breast cancer after prior breast radiotherapy. | Represents current-care options for this population: standard fractionated partial breast reirradiation or mastectomy, used outside clinical trials for similar patients. |
| Primary use | Treatment of in-breast recurrence or new primary breast cancer in patients previously irradiated, aiming to provide local tumor control with convenient, short radiotherapy regimen. | Treatment of in-breast recurrence with breast-conserving surgery followed by partial breast reirradiation (delivered over weeks), aiming for local control; mastectomy is chosen when reirradiation is not feasible. |
| How it is given or performed | External beam radiotherapy targeted to the partial breast region, 26Gy delivered in 5 daily fractions (1 week total). | Standard fractionated partial breast reirradiation: most protocols use 3D conformal RT or brachytherapy, typically delivered in smaller fractions over 1-3 weeks. Mastectomy involves surgical removal of the breast. |
| Evidence status | Ultra-hypofractionated partial breast reirradiation is under active clinical investigation for safety, local control, and patient outcomes; results for efficacy and toxicity are not yet established. | Partial breast reirradiation using standard fractionation is supported by phase 2 results, which show local control and manageable toxicity in selected patients. Mastectomy offers definitive tumor removal, but more extensive surgery. |
| Important limitations | Risks and effectiveness of ultra-hypofractionated partial breast reirradiation are not yet established. The technique is experimental, and long-term data on safety and local control are lacking. | Partial breast reirradiation with standard fractionation is limited by cumulative toxicities and careful patient selection. Mastectomy is more invasive but avoids radiation risks. Both approaches may not be suitable for all patients depending on prior treatment and disease factors. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 week
Participants receive external beam partial breast re-irradiation (rPBI) of 26 Gy in 5 daily sessions over 1 week after breast-conserving surgery.
5 daily treatment visits
Duration - Up to 5 years
Participants are monitored regularly for radiation side effects, cancer recurrence, survival, and quality of life for up to 5 years after treatment.
Scheduled visits at 3 months, 1 year, 2 years, 3 years, 4 years, and 5 years post-treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Adrian Murray Brunt, Joanne S Haviland, Mark Sydenham...
https://pubmed.ncbi.nlm.nih.gov/32663119/Carlos H Barrios, Tomás Reinert, Gustavo Werutsky
https://pubmed.ncbi.nlm.nih.gov/30231347/Danielle Rodin, Bouchra Tawk, Osama Mohamad...
https://pubmed.ncbi.nlm.nih.gov/33453312/Michelle Cororve Fingeret, Summer Nipomnick, Michele Guindani...
https://pubmed.ncbi.nlm.nih.gov/25066586/Douglas W Arthur, Kathryn A Winter, Henry M Kuerer...
https://pubmed.ncbi.nlm.nih.gov/31750868/Jamal Khader, Rachel M Glicksman, Sara Mheid...
https://pubmed.ncbi.nlm.nih.gov/32926325/Yasmin Korzets, Grace Lee, Osvaldo Espin-Garcia...
https://pubmed.ncbi.nlm.nih.gov/31436745/Yehoda M Martei, Verna Vanderpuye, Beth A Jones
https://pubmed.ncbi.nlm.nih.gov/29959283/Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram...
https://pubmed.ncbi.nlm.nih.gov/30207593/Hikmat Abdel-Razeq, Asem Mansour, Dima Jaddan
https://pubmed.ncbi.nlm.nih.gov/32083950/University Health Network, Toronto
Lead Sponsor
Sunnybrook Health Sciences Centre
Collaborating Sponsor